8-K: SeaStar Medical Raises $3.3M via Warrant Exercise

SeaStar Medical Holding Corporation announced the exercise of certain outstanding warrants, generating approximately $3.3 million in gross proceeds.

Summary

• SeaStar Medical Holding Corporation entered into agreements on October 2, 2026, for the exercise of certain outstanding common stock purchase warrants.
• These warrants were exercised for cash at a reduced exercise price of $3.866 per share, resulting in approximately $3.3 million in gross proceeds before fees and expenses.
• In exchange for exercising these warrants, holders received new unregistered Series A and Series B warrants to purchase up to an aggregate of 854,002 shares of common stock.
• The new warrants have an exercise price of $3.616 per share, with Series A warrants expiring five years and Series B warrants expiring eighteen months from the effective date of a Resale Registration Statement.
• The company plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it successfully raised capital by exercising existing warrants at a discount, while also issuing new warrants, indicating continued investor confidence despite the discount.

Positives

• Successfully raised approximately $3.3 million in gross proceeds through the exercise of existing warrants.
• Secured new warrants (Series A and Series B) issued to warrant holders, indicating continued investor engagement.
• The exercise price reduction to $3.866 per share was accepted by warrant holders, facilitating the capital raise.
• The company has a clear intended use for the net proceeds: general corporate purposes, working capital, and capital expenditures.
• The shares of common stock issuable upon exercise of the Prior Warrants are covered by effective registration statements.

Negatives

• The exercise of warrants occurred at a reduced exercise price ($3.866) compared to their original exercise prices (ranging from $6.38 to $7.62).
• The company issued a significant number of new warrants (Series A and Series B) which could dilute existing shareholders upon exercise.
• The new warrants have a lower exercise price ($3.616) than the reduced exercise price of the Prior Warrants.
• The company agreed to file a Resale Registration Statement for the new warrants, incurring further administrative and potential legal costs.

Risks

• The issuance of new warrants could lead to future dilution of common stock.
• The company is subject to risks related to obtaining regulatory approval for its products and securing future financing.
• The forward-looking statements section highlights risks such as potential failure to achieve profitability, inability to secure financing, and product liability issues.

Future Outlook

The company intends to use the net proceeds for general corporate purposes, which may include additions to working capital and capital expenditures. The company has agreed to file a registration statement for the resale of shares issuable upon exercise of the new warrants within 30 days and to have it declared effective within 60-90 days.

Management Comments

• SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medicals common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the Prior Warrants), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggregate gross proceeds of approximately $3.3 million, before deducting placement agent fees and other offering expenses.

Industry Context

StockSavvy.ai notes that this type of financing, involving the exercise of existing warrants at a discount and the issuance of new warrants, is a common strategy for companies, particularly in the biotechnology and healthcare sectors, to raise capital. It can signal a need for funding for ongoing clinical trials or commercialization efforts, while also potentially diluting existing shareholders.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new warrants and the potential exercise of these warrants.
• Existing warrant holders are incentivized to exercise their warrants due to the reduced exercise price and the issuance of new warrants.
• The company secures additional capital for operations and strategic initiatives.

Next Steps

• File a Resale Registration Statement for the new warrants within 30 days of October 2, 2026.
• Use commercially reasonable efforts to have the Resale Registration Statement declared effective by the SEC within 60-90 days.
• Use net proceeds for general corporate purposes, including working capital and capital expenditures.
• The offering is expected to close on or about October 5, 2026.

Key Dates

Recommendation

The company successfully raised capital, which is positive. However, the discounted warrant exercise and the issuance of new warrants at a lower strike price introduce potential future dilution. The company's focus on critical care treatments and its FDA-approved product (QUELIMMUNE) are positive long-term factors, but the immediate financial maneuver warrants a cautious 'hold' until the impact of the new warrants and the progress of clinical trials (like NEUTRALIZE-AKI) become clearer.

Keywords

warrant exercise, capital raise, SeaStar Medical, common stock, healthcare, placement agent, registration statement, dilution